acute brain injury acute cerebral ischemia
Conditions
Interventions
None listed
Sponsors
IC
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Healthy men or women of 18-35 years old
Exclusion criteria
Exclusion criteria: - Hypersensitivity to the active substance(s) or to any of the excipients in SonoVue - Right-to-left shunt cardiac shunt - Severe pulmonary hypertension (pulmonary artery pressure >90 mmHg) - Uncontrolled systemic hypertension - Pregnancy - Lactation - Participation in another clinical trial within 3 months prior to the experimental day. - History, signs, or symptoms of cardiovascular disease or pulmonary disease - History, signs or symptoms of neurological disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main study parameter is the reproducibility of the CEUS bolus kinetics using the simultaneous measurement in the internal carotid artery and middle cerebral artery. Measurements of the brain will be performed at normoventilation by a single investigator, the differences between the 3 subsequent measurements will be compared (all measurements performed within 90 minutes). A difference between the measurements of more than 10% is considered to imply poor reproducibility. As a control, the reproducib¡lity of measurement of the flow velocity in the ipsilateral middle cerebral artery will be assessed. The investigator performing the test is blinded for the results, as determination of flow is only possible after offline analysis. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary study parameters are - Variability of the CEUS technique without the baseline measurement at the internal carotid artery - Correlation between flow measurements using the CEUS bolus technique (using the signal in the internal carotid artery as a baseline signal) with CBF measured with transcranial Doppler in normal en decreased CBF - Correlation between flow measurements using the CEUS bolus techn¡que (not using the signal in the internal carotid artery as a baseline signal) with CBF measured with transcranial Doppler in normal en decreased CBF | — |
Countries
Netherlands
Outcome results
None listed